BRAF Mutation in Melanoma
The FDA recently cleared Zelboraf™ (Vemurafenib) for the treatment of unresectable or metastatic melanoma patients with BRAF V600E mutation-positive tumors. Zelboraf significantly improved overall survival in people with previously untreated BRAF V600E mutation-positive metastatic melanoma, compared to chemotherapy.
BRAF V600E gene mutation is present in 30-60% of cutaneous melanomas.
Click here for a Case Study
Cutaneous Lymphoproliferative Disorders
Molecular characterization of T-cell receptor gene rearrangements and immunoglobulin heavy and light chain gene rearrangement detection is accomplished with reliable and robust tests to identify clonal T-cell and B-cell populations in a variety of cutaneous lymphoproliferative disorders.
While the demonstration of a clonal T/B cell population is not necessarily reflective of a truly pathologic process, positive results interpreted in the context of all laboratory findings can support diagnosis of malignancy. The ability to routinely perform these studies make these highly sensitive and specific tests well suited for the evaluation of these conditions.Test Information and Specimen Requirments
BRAF Contact Form
For more information about BRAF or gene rearrangement analysis, contact a service specialist at 800-932-2943.
Chapman, et al. (2011). Improved survival in Melanoma with BRAF V600E mutation. NEJM; 364:2507-2516